Promising targeted treatments and immunotherapy strategies in oncology and advancements
in our understanding of molecular pathways that underpin cancer development have …

ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive
patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC…

The immune system employs several checkpoint pathways to regulate responses, maintain
homeostasis and prevent self-reactivity and autoimmunity. Tumor cells can hijack these …

Host-induced antibodies and their contributions to cancer inflammation are largely unexplored.
IgG4 subclass antibodies are present in IL-10–driven Th2 immune responses in some …

Cytotoxic T‐lymphocyte associated protein‐4 (CTLA‐4) and the Programmed Death Receptor
1 (PD‐1) are immune checkpoint molecules that are well‐established targets of antibody …

Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy, combining
the antibody's exquisite specificity for the target antigen-expressing cancer cell together …

ROCK-Myosin II drives fast rounded-amoeboid migration in cancer cells during metastatic
dissemination. Analysis of human melanoma biopsies revealed that amoeboid melanoma …

Background Using an updated dataset with more patients and extended follow-up, we further
established cancer patient characteristics associated with COVID-19 death. Methods Data …

Over the last four decades, molecular cloning has evolved tremendously. Efficient products
allowing assembly of multiple DNA fragments have become available. However, cost-…

Outcomes for half of patients with melanoma remain poor despite standard-of-care checkpoint
inhibitor therapies. The prevalence of the melanoma-associated antigen chondroitin …